Trial Profile
Prospective Non-interventional Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 03 Apr 2024
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary) ; Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- Acronyms CABOCARE
- Sponsors Ipsen
- 18 Dec 2023 Addition of primary endpoint Number of injection delayed of nivolumab due to SAE/AE[ Time Frame: 2 years ]
- 18 Dec 2023 Planned number of patients changed from 105 to 210.
- 18 Dec 2023 Planned End Date changed from 31 Aug 2026 to 30 Sep 2027.